Skip to main content

Advertisement

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Article metrics

  • 610 Accesses

The original article was published in Arthritis Research & Therapy 2019 21:79

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1856-4

Following publication of the original article [1], the authors reported an error in Table 2. The data for ‘HAQ-DI response (MCID ≥ 0.3), n (%) / At week 52’ for the ‘Sarilumab 150 mg q2w + MTX’ and ‘Sarilumab 200 mg q2w + MTX’ groups should be 41 (50.6) and 37 (46.3), respectively (last row, last two entries of the table).

The corrected table is given below.

Table 2 Efficacy results (mITT population)

Reference

  1. 1.

    Tanaka, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21:79. https://doi.org/10.1186/s13075-019-1856-4.

Download references

Author information

Correspondence to Yoshiya Tanaka.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tanaka, Y., Wada, K., Takahashi, Y. et al. Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther 21, 99 (2019) doi:10.1186/s13075-019-1887-x

Download citation